Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 23;5(2):e423.
doi: 10.1097/TXD.0000000000000861. eCollection 2019 Feb.

Effects of Telmisartan and Candesartan on the Metabolism of Lipids and Glucose in Kidney Transplant Patients: A Prospective, Randomized Crossover Study

Yoshifumi Miura  1 , Hiroshi Noguchi  1 , Yasuhiro Okabe  1 , Kosuke Masutani  2 , Shoji Tokunaga  3 , Masafumi Nakamura  1
Affiliations

Effects of Telmisartan and Candesartan on the Metabolism of Lipids and Glucose in Kidney Transplant Patients: A Prospective, Randomized Crossover Study

Yoshifumi Miura et al. Transplant Direct. .

Abstract

Background: The risk of cardiovascular events remains after kidney transplantation (KT). Abnormal glucose metabolism and hyperlipidemia contribute partly to this risk. Among angiotensin II type-1 receptor blockers, telmisartan alone has been shown to ameliorate these effects on glucose and lipid metabolism (GLM). We investigated the effects of telmisartan on GLM in KT patients.

Methods: This trial had a crossover design. Forty-six KT patients with well-controlled hypertension under angiotensin II type-1 receptor blockers were randomized into telmisartan and candesartan groups. After a 12-week treatment, crossover was initiated, and additional 12-week treatment was administered without a washout period. We examined the laboratory parameters of GLM, blood pressure and graft function before and after each treatment period.

Results: Forty patients completed the scheduled treatment regimen. Serum levels of triglyceride were significantly lower (114.3 ± 50.8 mg/dL vs 136.5 ± 66.8 mg/dL; P = 0.019), and the estimated glomerular filtration rate was significantly higher (50.4 ± 15.1 mL/min per 1.73 m2 vs 48.5 ± 12.5 mL/min per 1.73 m2; P = 0.038) after telmisartan treatment than after candesartan treatment. There were no significant differences between the 2 treatment groups with regard to the other parameters studied (including serum adiponectin levels and parameters of glucose metabolism).

Conclusions: These data suggest that telmisartan can improve serum triglyceride levels and graft function for KT patients better than candesartan.

PubMed Disclaimer

Conflict of interest statement

The Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University received scholarship donations from Astellas Pharma. This study was conducted under the regulation of “Kyushu University Policy of Conflicts of Interest.”

Figures

FIGURE 1
FIGURE 1
Crossover study design. Assessments were made at 0, 12, and 24 weeks after randomization.
See this image and copyright information in PMC

References

    1. Pascual J, Zamora J, Pirsch JD. A systematic review of kidney transplantation from expanded criteria donors. Am J Kidney Dis. 2008;52:553–586. - PubMed
    1. Toussaint C, Kinnaert P, Vereerstraeten P. Late mortality and morbidity five to eighteen years after kidney transplantation. Transplantation. 1988;45:554–558. - PubMed
    1. Kasiske BL. Ischemic heart disease after renal transplantation. Kidney Int. 2002;61:356–369. - PubMed
    1. Veenstra DL, Best JH, Hornberger J, et al. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis. 1999;33:829–839. - PubMed
    1. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study group. Transplantation. 1997;63:977–983. - PubMed